{"id":"tnm002","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"},{"rate":"5-10%","effect":"Cough"},{"rate":"5-10%","effect":"Dyspnea"},{"rate":"5-10%","effect":"Arthralgia"},{"rate":"1-5%","effect":"Pneumonia"},{"rate":"1-5%","effect":"Pneumonitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TNM002 works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells and thereby enhancing T cell-mediated anti-tumor responses.","oneSentence":"TNM002 is a monoclonal antibody targeting PD-1.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:54:17.107Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT05625477","phase":"PHASE2","title":"Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers","status":"COMPLETED","sponsor":"Zhuhai Trinomab Pharmaceutical Co., Ltd.","startDate":"2022-04-18","conditions":"Tetanus","enrollment":240},{"nctId":"NCT06607380","phase":"PHASE1","title":"A Randomized, Open-Label, Parallel-Design Pharmacokinetic and Pharmacodynamic Interaction Study of TNM002 and Adsorbed Tetanus Vaccine","status":"COMPLETED","sponsor":"Zhuhai Trinomab Pharmaceutical Co., Ltd.","startDate":"2022-08-13","conditions":"Tetanus","enrollment":60},{"nctId":"NCT05664750","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus","status":"COMPLETED","sponsor":"Zhuhai Trinomab Pharmaceutical Co., Ltd.","startDate":"2022-12-22","conditions":"Tetanus","enrollment":675},{"nctId":"NCT05842798","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Chinese Healthy Adults","status":"COMPLETED","sponsor":"Zhuhai Trinomab Pharmaceutical Co., Ltd.","startDate":"2021-10-15","conditions":"Healthy Volunteers","enrollment":28},{"nctId":"NCT04629131","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Healthy Adults","status":"COMPLETED","sponsor":"Zhuhai Trinomab Pharmaceutical Co., Ltd.","startDate":"2020-11-25","conditions":"Healthy Adult Subjects","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TNM002","genericName":"TNM002","companyName":"Zhuhai Trinomab Pharmaceutical Co., Ltd.","companyId":"zhuhai-trinomab-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TNM002 is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}